Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Ovarian Neoplasms 17Breast Neoplasms 16Lung Neoplasms 15Endometrial Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 12Fallopian Tube Neoplasms 10Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 8Triple Negative Breast Neoplasms 6Esophageal Neoplasms 5Adenocarcinoma Of Esophagus 5Stomach Neoplasms 4Neoplasms 4Melanoma 4Esophageal Squamous Cell Carcinoma 4Colorectal Neoplasms 3Cholangiocarcinoma 3Carcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Peritoneal Neoplasms 2Carcinoma, Transitional Cell 2Brenner Tumor 2Anatomic Stage I Breast Cancer AJCC v8 2Advanced Solid Tumour 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2Adenocarcinoma 2Uterine Neoplasms 1

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Paclitaxel × 30 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡